These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 25340597)

  • 1. De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection.
    Chemouny JM; Suberbielle C; Rabant M; Zuber J; Alyanakian MA; Lebreton X; Carmagnat M; Pinheiro N; Loupy A; Van Huyen JP; Timsit MO; Charron D; Legendre C; Anglicheau D
    Transplantation; 2015 May; 99(5):965-72. PubMed ID: 25340597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute cellular rejection: impact of donor-specific antibodies and C4d.
    Willicombe M; Roufosse C; Brookes P; McLean AG; Galliford J; Cairns T; Cook TH; Taube D
    Transplantation; 2014 Feb; 97(4):433-9. PubMed ID: 24430742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression patterns of B cells in acute kidney transplant rejection.
    Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
    Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of pathologic changes in kidney allografts of positive crossmatch HLA-incompatible transplant recipients.
    Bagnasco SM; Zachary AA; Racusen LC; Arend LJ; Carter-Monroe N; Alachkar N; Nazarian SM; Lonze BE; Montgomery RA; Kraus ES
    Transplantation; 2014 Feb; 97(4):440-5. PubMed ID: 24531821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
    Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
    Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo donor-specific HLA antibodies reduce graft survival rates and increase the risk of kidney transplant rejection: A single-center retrospective study.
    Liu W; Zhao J; Kang ZY; Xiao YL; Yang L; Liu C; Li DH
    Transpl Immunol; 2021 Oct; 68():101430. PubMed ID: 34147608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Cardeau-Desangles I; Guitard J; Dörr G; Milongo D; Suc B; Duffas JP; Alric L; Bureau C; Guilbeau-Frugier C; Rostaing L; Kamar N
    Transpl Int; 2015 Dec; 28(12):1371-82. PubMed ID: 26303035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rejection of the Renal Allograft in the Absence of Demonstrable Antibody and Complement.
    Zhao X; Huang G; Randhawa S; Zeng G; Lunz J; Randhawa P
    Transplantation; 2017 Feb; 101(2):395-401. PubMed ID: 26901079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretransplant immunologic risk assessment of kidney transplant recipients with donor-specific anti-human leukocyte antigen antibodies.
    Marfo K; Ajaimy M; Colovai A; Kayler L; Greenstein S; Lubetzky M; Gupta A; Kamal L; de Boccardo G; Masiakos P; Kinkhabwala M; Akalin E
    Transplantation; 2014 Nov; 98(10):1082-8. PubMed ID: 24873780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts.
    Everly MJ; Rebellato LM; Haisch CE; Ozawa M; Parker K; Briley KP; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC; Terasaki PI
    Transplantation; 2013 Feb; 95(3):410-7. PubMed ID: 23380861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.
    Gill JS; Landsberg D; Johnston O; Shapiro RJ; Magil AB; Wu V; Tinckam K; Keown P
    Transplantation; 2010 Jan; 89(2):178-84. PubMed ID: 20098280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation.
    Heilman RL; Nijim A; Desmarteau YM; Khamash H; Pando MJ; Smith ML; Chakkera HA; Huskey J; Valdez R; Reddy KS
    Transplantation; 2014 Dec; 98(12):1310-5. PubMed ID: 24879384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation.
    Caro-Oleas JL; González-Escribano MF; Gentil-Govantes MÁ; Acevedo MJ; González-Roncero FM; Blanco GB; Núñez-Roldán A
    Transplantation; 2012 Aug; 94(4):338-44. PubMed ID: 22814330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.